Drug Price Trends for test

Average Pharmacy Cost for test

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
TESTOSTERON ENAN 1,000 MG/5 ML	00143-9750-01	14.76113	ML	2026-06-17
TESTOSTERONE 1.62% GEL PUMP	00591-2924-18	0.47714	GM	2026-06-17
TESTOSTERONE 1.62% (2.5 G) PKT	00591-2926-30	2.10958	GM	2026-06-17
TESTOSTERONE ENAN 200 MG/ML	00591-3221-26	14.76113	ML	2026-06-17
TESTOSTERONE 1.62% (2.5 G) PKT	16714-0969-02	2.10958	GM	2026-06-17
TESTOSTERONE 1.62% (2.5 G) PKT	45802-0366-65	2.10958	GM	2026-06-17
TESTIM 1% (50 MG) GEL	66887-0001-05	3.78047	GM	2026-06-17

Best Wholesale Price for test

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
KYZATREX 200MG CAP	Marius Pharmaceuticals LLC	80603-0105-22	120	115.58	0.96317	EACH	2024-02-01 - 2029-01-31	FSS
KYZATREX 100MG CAP	Marius Pharmaceuticals LLC	80603-0101-22	120	91.91	0.76592	EACH	2024-02-01 - 2029-01-31	Big4
KYZATREX 200MG CAP	Marius Pharmaceuticals LLC	80603-0105-22	120	98.17	0.81808	EACH	2024-04-09 - 2029-01-31	Big4
KYZATREX 100MG CAP	Marius Pharmaceuticals LLC	80603-0101-22	120	105.53	0.87942	EACH	2024-02-01 - 2029-01-31	FSS
KYZATREX 100MG CAP	Marius Pharmaceuticals LLC	80603-0101-22	120	92.00	0.76667	EACH	2024-04-09 - 2029-01-31	Big4
KYZATREX 150MG CAP	Marius Pharmaceuticals LLC	80603-0103-22	120	91.61	0.76342	EACH	2024-02-01 - 2029-01-31	Big4
KYZATREX 150MG CAP	Marius Pharmaceuticals LLC	80603-0103-22	120	115.58	0.96317	EACH	2024-02-01 - 2029-01-31	FSS

Last updated: July 14, 2026

Market analysis and price projections for “test” drug (not usable for patent/market modeling)

What is the FDA status of the “test” drug and what does its regulatory pathway imply for launch timing?

No market or price projection can be produced because the drug name provided is not an identifiable active ingredient, brand, strength, dosage form, manufacturer, or FDA-approved product.

What is the Orange Book status of “test” and how does exclusivity affect generic and biosimilar entry?

No Orange Book analysis is possible because “test” does not map to a specific FDA product record, NDC, or listed drug.

Which companies manufacture “test” and what is the competitive landscape for the same active ingredient?

No competitive landscape can be constructed because the target active ingredient and product identity are not specified.

When would generic entry occur for “test” under Hatch-Waxman, and what triggers Paragraph IV risk?

Generic timing depends on the listed drug, patent numbers, expiration dates, and any granted exclusivities. None can be determined from “test.”

What price benchmarks apply to “test” based on similar drugs, dose, and payer mix?

Pricing benchmarks require at minimum: molecule/indication class, route of administration, dosage strength, and approved use. Those details are not provided.

How should “test” prices evolve post-launch, and what are the likely net price vs WAC trajectories?

Net price projections require payer contracting patterns tied to product identity, specialty vs non-specialty channel, and utilization. Those cannot be derived from “test.”

What patent estate strength and litigation history affect pricing power for “test”?

Patent strength and litigation risk depend on the specific patent family, claims, and current status. None can be identified for “test.”

What revenue exposure exists for payers and investors under different entry scenarios for “test”?

Revenue exposure is scenario-based on expected market size, time to entry, and forecast unit demand by indication. None can be computed without the drug’s identity.

Key Takeaways

• No actionable market analysis or price projections can be produced from the input “test” because it is not an identifiable drug product.
• Patent exclusivity, Orange Book status, competitive entrants, and launch timing cannot be mapped.
• Pricing forecasts require the specific active ingredient, dosage form, strength, and FDA-approved label.

FAQs

1. How do you estimate future pricing for a drug without knowing its active ingredient and formulation?
2. What Orange Book data points drive generic launch timing under Hatch-Waxman?
3. How does patent litigation posture typically influence net pricing and contracting leverage?
4. What inputs are required for a scenario model of revenue impact from Paragraph IV filings?
5. How do dose and route of administration change benchmarking for specialty pharmacy pricing?

References

No references provided because no drug identity was specified.